These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29707916)

  • 21. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease.
    Tomaschitz A; Ritz E; Pieske B; Fahrleitner-Pammer A; Kienreich K; Horina JH; Drechsler C; März W; Ofner M; Pieber TR; Pilz S
    Cardiovasc Res; 2012 Apr; 94(1):10-9. PubMed ID: 22334595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function.
    Bleskestad IH; Bergrem H; Leivestad T; Hartmann A; Gøransson LG
    Clin Transplant; 2014 Apr; 28(4):479-86. PubMed ID: 25649861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium modulation of the renin-aldosterone axis.
    Porter L; Conlin PR; Scott J; Brown EM; El-Hajj Fuleihan G
    J Endocrinol Invest; 1999 Feb; 22(2):115-21. PubMed ID: 10195378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.
    Slinin Y; Foley RN; Collins AJ
    J Am Soc Nephrol; 2005 Jun; 16(6):1788-93. PubMed ID: 15814832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can parathyroid hormone be used as a biomarker for heart failure?
    Gandhi S; Myers RB
    Heart Fail Rev; 2013 Jul; 18(4):465-73. PubMed ID: 22875486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between Parathyroid Hormone, 25 (OH) Vitamin D, and Chronic Kidney Disease: A Population-Based Study.
    Wang WH; Chen LW; Lee CC; Sun CY; Shyu YC; Hsu HR; Chien RN; Wu IW
    Biomed Res Int; 2017; 2017():7435657. PubMed ID: 28367447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
    Akiba T
    Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community.
    Hagström E; Hellman P; Larsson TE; Ingelsson E; Berglund L; Sundström J; Melhus H; Held C; Lind L; Michaëlsson K; Arnlöv J
    Circulation; 2009 Jun; 119(21):2765-71. PubMed ID: 19451355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parathyroid enlargement at dialysis initiation in patients with chronic kidney diseases.
    Nakai K; Fujii H; Kono K; Goto S; Miura S; Maeda A; Takeda K; Nishi S
    Ther Apher Dial; 2013 Feb; 17(1):24-9. PubMed ID: 23379489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association of chronic kidney disease-mineral bone disorder and cardiovascular risk.
    Eddington H; Kalra PA
    J Ren Care; 2010 May; 36 Suppl 1():61-7. PubMed ID: 20586901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioactive parathyroid hormone in canine progressive renal insufficiency.
    Grunbaum D; Wexler M; Antos M; Gascon-Barré M; Goltzman D
    Am J Physiol; 1984 Oct; 247(4 Pt 1):E442-8. PubMed ID: 6496665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary phosphorus and kidney disease.
    Uribarri J
    Ann N Y Acad Sci; 2013 Oct; 1301():11-9. PubMed ID: 23876096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium and phosphate homeostasis in hyperthyroid cats: associations with development of azotaemia and survival time.
    Williams TL; Elliott J; Syme HM
    J Small Anim Pract; 2012 Oct; 53(10):561-71. PubMed ID: 22860883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of keto acids on serum parathyroid hormone levels in patients with chronic renal failure.
    Fröhling PT; Kokot F; Schmicker R; Kaschube I; Lindenau K; Vetter K
    Clin Nephrol; 1983 Oct; 20(4):212-5. PubMed ID: 6641029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.
    Whaley-Connell A; Pavey BS; Chaudhary K; Saab G; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):27-35. PubMed ID: 19124393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
    Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
    Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
    Soriano S; Ojeda R; Rodríguez M; Almadén Y; Rodríguez M; Martín-Malo A; Aljama P
    Clin Nephrol; 2013 Jul; 80(1):17-22. PubMed ID: 23391319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.